Antiangiogenic Approaches to Age-Related Macular Degeneration Today

Ophthalmology

Volumn 116, Issue 10 SUPPL., 2009, Pages

  Bressler, Neil M ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; RANIBIZUMAB;

ANTIANGIOGENIC ACTIVITY; ARTICLE; BRAIN HEMORRHAGE; DISEASE COURSE; DRUG EFFICACY; ENDOPHTHALMITIS; FLUORESCENCE ANGIOGRAPHY; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; INTRAOCULAR HEMORRHAGE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RISK BENEFIT ANALYSIS; RISK REDUCTION; SUBCONJUNCTIVAL HEMORRHAGE; SUBRETINAL NEOVASCULARIZATION; TRANSIENT ISCHEMIC ATTACK; VISUAL ACUITY; VITREOUS FLOATERS;

ALGORITHMS; ANGIOGENESIS INHIBITORS; ANIMALS; CLINICAL TRIALS AS TOPIC; DECISION SUPPORT TECHNIQUES; HUMANS; MACULAR DEGENERATION; PHOTOCHEMOTHERAPY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 70349469696     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2009.06.048     Document Type: Article

References (41)

1. Shams N., and Ianchulev T. Role of vascular endothelial growth factor in ocular angiogenesis. Ophthalmol Clin North Am 19 (2006) 335-344
2. Kvanta A., Algvere P.V., Berglin L., and Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 37 (1996) 1929-1934
3. Rosenfeld P.J., Brown D.M., Heier J.S., et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1419-1431
4. Brown D.M., Kaiser P.K., Michels M., et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1432-1444
5. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 109 (1991) 1220-1231
6. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 109 (1991) 1232-1241
7. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol 117 (1999) 1329-1345
8. Hawkins B.S., Bressler N.M., Miskala P.H., et al. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: ophthalmic findings: SST report no. 11. Ophthalmology 111 (2004) 1967-1980
9. Marcus D.M., Peskin E., Maguire M., et al. The age-related macular degeneration radiotherapy trial (AMDRT): one year results from a pilot study. Am J Ophthalmol 138 (2004) 818-828
10. Gragoudas E.S., Adamis A.P., Cunningham Jr. E.T., et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351 (2004) 2805-2816
11. Brown D.M., Michels M., Kaiser P.K., et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 116 (2009) 57-65
12. Miskala P.H., Bass E.B., Bressler N.M., et al. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: quality-of-life findings: SST report no. 12. Ophthalmology 111 (2004) 1981-1992
13. Chang T.S., Bressler N.M., Fine J.T., et al. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 125 (2007) 1460-1469
14. Chang T.S., Bressler N.M., Fine J.T., et al. Improved Vision-Related Function After Ranibizumab Treatment of Neovascular AMD: results of a randomized clinical trial. Arch Ophthalmol 125 (2007) 1460-1469
15. Bressler N.M., Chang T.S., Fine J.T., et al. Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Arch Ophthalmol 127 (2009) 13-21
16. Lucentis (ranibizumab injection) (2007), Genentech, Inc, South San Francisco
17. Ta C.N. Minimizing the risk of endophthalmitis following intravitreous injections. Retina 24 (2004) 699-705
18. Lauer G., Sollberg S., Cole M., et al. Expression and proteolysis of vascular endothelial growth factor is increased in chronic wounds. J Invest Dermatol 115 (2000) 12-18
19. Carmeliet P., Ng Y.S., Nuyens D., et al. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat Med 5 (1999) 495-502
20. Alexander S.L., Linde-Zwirble W.T., Werther W., et al. Annual rates of arterial thromboembolic events in Medicare neovascular age-related macular degeneration patients. Ophthalmology 114 (2007) 2174-2178
21. Rosamond W., Flegal K., Friday G., et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115 (2007) e69-e171
22. Ferrara N., Damico L., Shams N., et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26 (2006) 859-870
23. "Dear Doctor" letter. Genentech, Inc. http://www.gene.com/gene/products/information/pdf/healthcare-provider-letter.pdf Accessed September 27, 2008
24. Rosenfeld P.J., Schwartz S.D., Blumenkranz M.S., et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 112 (2005) 1048-1053
25. Rosenfeld P.J., Moshfeghi A.A., and Puliafito C.A. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36 (2005) 331-335
26. Avery R.L., Pieramici D.J., Rabena M.D., et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113 (2006) 363-372
27. Bashshur Z.F., Bazarbachi A., Schakal A., et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 142 (2006) 1-9
28. Diabetic Retinopathy Clinical Research Network. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 114 (2007) 1860-1867
29. Wu L., Martinez-Castellanos M.A., Quiroz-Mercado H., et al., Pan American Collaborative Retina Group. Twelve-month safety of intravitreal injections of bevacizumab (Avastin1): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 246 (2008) 81-87
30. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Arch Ophthalmol 109 (1991) 1109-1114
31. Macular Photocoagulation Study Group. Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study. Arch Ophthalmol 109 (1991) 1242-1257
32. Arnold J.J., Blinder K.J., Bressler N.M., et al. Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials-TAP and VIP report no. 3. Am J Ophthalmol 137 (2004) 683-696
33. Solomon S.D., Bressler S.B., Hawkins B.S., et al. Guidelines for interpreting retinal photographs and coding findings in the Submacular Surgery Trials (SST): SST report no. 8. Retina 25 (2005) 253-268
34. Chang L.K., and Sarraf D. Tears of the retinal pigment epithelium: an old problem in a new era. Retina 27 (2007) 523-534
35. Gillies A., and Lahav M. Absorption of retinal and subretinal hemorrhages. Ann Ophthalmol 15 (1983) 1068-1074
36. Macular Photocoagulation Study Group. The influence of treatment extent on the visual acuity of eyes treated with Krypton laser for juxtafoveal choroidal neovascularization. Arch Ophthalmol 113 (1995) 190-194
37. Beck R.W., Maguire M.G., Bressler N.M., et al. Visual acuity as an outcome measure in clinical trials of retinal diseases. Ophthalmology 114 (2007) 1804-1809
38. Blackhurst D.W., and Maguire M.G. Reproducibility of refraction and visual acuity measurement under a standard protocol. The Macular Photocoagulation Study Group. Retina 9 (1989) 163-169
39. Regillo C.D., Brown D.M., Abraham P., et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study Year 1. Am J Ophthalmol 145 (2008) 239-248
40. Fung A., Lalwani G.A., Rosenfeld P.J., et al., PIER Study Group. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143 (2007) 566-583
41. Cohen S.Y., Dubois L., Tadayoni R., et al. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. Am J Ophthalmol 148 (2009) 409-413 [Epub ahead of print May 24]